Tharimmune Executa Pivot Estratégico para Ativos Digitais e Levanta Impressionantes US$ 540 Milhões em Colocação Privada

Empresa de biotecnologia surpreende mercados com mudança radical para criptomoedas

O movimento ousado da Tharimmune representa uma das maiores captações do ano no espaço digital - levantando cerca de US$ 540 milhões através de colocação privada enquanto abandona seu modelo de negócios anterior.

Investidores institucionais aparentemente esqueceram que diversificação normalmente significa mais de uma classe de ativos, não trocar completamente de cavalo no meio do rio.

Especialistas do mercado questionam se esta é uma jogada visionária ou apenas mais uma empresa buscando o brilho artificial dos ativos digitais enquanto os fundamentos originais desmoronam.

A corrida do ouro digital continua - porque afinal, por que curar doenças quando você pode especular com tokens?

DRW and Liberty City Ventures led the funding 

Per the firm’s announcement, DRW and Liberty City Ventures were the lead investors. However, other prominent investors involved included ARK Invest, Bitwave, Broadridge, Clear Street, Copper, Digital Asset, Feynman Point Asset Management, Five North, Kaiko, Kenetic, Kraken, LendOS, Lukka, Nima Capital, MPCH, Obsidian Software, Polychain Capital, Proof Group, SBI Group, The Tie, Tradeweb Markets, and 7RIDGE. 

The Canton Foundation, Canton Network’s governing body, also participated in the offering, making Tharimmune the first and only publicly traded company supported by the Canton Foundation. 

The offering is expected to close on or about November 6, 2025, subject to the satisfaction of customary closing conditions, and net proceeds of the offering will be used to acquire Canton Coin (“CC”), a utility token used to support interoperability and settlement across the Canton Network, as well as for working capital and general corporate purposes. 

Upon the closing of the offering, the company claims it will execute a diverse strategy that, along with CC acquisition via capital markets activities, includes the generation of CC rewards by applying to be a super validator and investing in the development of applications on the Canton Network that encourage institutional utility, scalability, and adoption across capital markets.

The strategy is being touted as Tharimmune’s confidence in Canton’s blockchain technology reshaping financial infrastructure. 

Tharimmune, Inc. joins the ranks of medical firms with DATs

Crypto has been getting more popular among industries since it gained a foothold in the corridors of power. Tharimmune, a medically-focused company, is the latest rebranding to buy crypto.

Helius Medical Technologies, another neurotech medical device company focused on treating different neurological deficits, also pivoted into a digital asset treasury in September. TNF Pharmaceuticals, another clinical-stage research company, also announced a complete strategic pivot and rebrand to Q/C Technologies. 

As part of the Helius rebranding, the company announced it would create a digital asset treasury (DAT) centered around SOL purchases after raising $500 million dedicated to funding its cryptocurrency treasury strategy.

If you're reading this, you’re already ahead. Stay there with our newsletter.